New Zealand has the world's highest rates of serious illness caused by RSV, with 2000 children under five admitted to ...

MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce ...

Vulnerable Australians aged 50-59 will be able to receive a vaccine for respiratory syncytial virus (RSV).

Pfizer PFE reported first-quarter 2025 adjusted earnings per share of 92 cents, which comprehensively beat the Zacks ...

It is still very early days, but GSK’s respiratory syncytial virus (RSV) Arexvy seems to have flown out of the traps more quickly than Pfizer’s rival shot Abrysvo in the first weeks since they ...

At the moment, Pfizer's Abrysvo and Moderna's mResvia – currently the only other approved RSV vaccines in the EU for older adults – are only approved for the over-60 age bracket, so Arexvy has ...

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

ACIP is recommending that adults aged 50 to 59 years who are at increased risk for severe RSV disease receive a single dose of an RSV vaccine.